Estrogen and the risk of breast cancer

New England Journal of Medicine

Volumn 344, Issue 4, 2001, Pages 276-285

  Clemons, Mark ^a   Goss, Paul ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; PHYTOESTROGEN;

ADULT; AGED; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; ESTROGEN SYNTHESIS; ESTROGEN THERAPY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

BONE DENSITY; BREAST; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MALE; MAMMOGRAPHY; RISK FACTORS;

EID: 0035945656     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200101253440407     Document Type: Review

References (102)

1. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases
2. Estrogen use and cancer incidence: A review
3. Hormones and mammary carcinogenesis in mice, rats, and humans: A unifying hypothesis
4. Molecular mechanisms of estrogen carcinogenesis
5. Endogenous hormones as a major factor in human cancer
6. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk
7. Epidemiologic analysis of breast and gynecologic cancers
8. Proportion of breast cancer cases in the United States explained by well-established risk factors
9. Use of oral contraceptives and risk of breast cancer in young women
10. Breast cancer and hormonal contraceptives
11. Breast cancer in Swedish women before age 50: Evidence of a dual effect of completed pregnancy
12. Age at first full-term pregnancy, lactation and parity and risk of breast cancer: A case-control study in Spain
13. Parity, age at first and last birth, and risk of breast cancer: A population-based study in Sweden
14. Breastfeeding experience and breast cancer risk among postmenopausal women
15. Postmenopausal hormone therapy and mortality
16. A prospective study of endogenous estrogens and breast cancer in postmenopausal women
17. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey
18. A Prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey
19. Quantitative classification of mammographic densities and breast cancer risk: Results from the Canadian National Breast Screening Study
20. Bone mineral density and risk of breast cancer in older women: The study of osteoporotic fractures
21. Bone mass and the risk of breast cancer among postmenopausal women
22. Nurses' Health Study: Log-incidence mathematical model of breast cancer incidence
23. Characteristics that predict risk of breast cancer before and after menopause
24. Joint effects on cancer risk of age at childbirth, time since birth and attained age: Circumventing the problem of collinearity
25. Biochemical control of breast development
26. Re: Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status
27. Do regular ovulatory cycles increase breast cancer risk?
28. Case-control study of breast cancer in southeast England: Nutritional factors
29. Association of dietary intake of fat and fatty acids with risk of breast cancer
30. Protection against cancer by wheat bran: Role of dietary fibre and phytochemicals
31. Dietary carotenoids and vitamins A, C, and E and risk of breast cancer
32. Intake of food groups and associated micronutrients in relation to risk of early-stage breast cancer
33. Flaxseed and its lignan and oil components reduce mammary tumor growth at a late stage of carcinogenesis
34. Phytoestrogens: The "natural" selective estrogen receptor modulators?
35. Phytoestrogens and breast cancer
36. Soy intake and risk of breast cancer in Asians and Asian Americans
37. A prospective study of oral contraceptive use and risk of breast cancer (Nurses' Health Study, United States)
38. Recent oral contraceptive use and risk of breast cancer
39. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives
40. Oral contraceptive use at a young age and the risk of breast cancer: An Icelandic, population-based cohort study of the effect of birth year
41. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies
42. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?
43. Breast cancer in young women and use of oral contraceptives: Possible modifying effect of formulation and age at use
44. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer
45. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement
46. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy
47. Menopansal estrogen and estrogen-progestin replacement therapy and breast cancer risk
48. Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women
49. Enzymatic control of estrogen production in human breast cancer: Relative significance of aromatase versus sulfatase pathways
50. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer
51. Association between CYP17 polymorphisms and the development of breast cancer
52. CYP17 genotype and breast cancer risk
53. A polymorphism in the CYP17 gene increases the risk of breast cancer
54. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk
55. Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis
56. Aromatase gene expression and its exon I usage in human breast tumors: Detection of aromarase messenger RNA by reverse transcription-polymerase chain reaction
57. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation
58. Characterization of a novel silencer element in the human aromatase gene PII promoter
59. Estrogen receptor expression of benign breast epithelium and its association with breast cancer
60. Oestrogen receptor expression in the normal and pre-cancerous breast
61. Low oestrogen receptor alpha expression in normal breast tissue underlies low breast cancer incidence in Japan
62. Estrogen receptor-positive proliferating cells in the normal and precancerous breast
63. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens
64. Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis
65. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up
66. Urinary estrogen metabolites and breast cancer: A case-control study
67. Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women
68. Cigarette smoking and urinary oestrogen excretion in premenopausal and postmenopausal women
69. Smoking and risk of endometrial cancer: Results from an Italian case-control study
70. Cigarette smoking and breast cancer risk among young women (United States)
71. Covariance of breast cancer incidence with smoking-, oestrogen- and diet-related cancers in pre- and postmenopausal women in Sweden
72. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women
73. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer
74. Steroid dynamics in the normal and carcinomatous mammary gland
75. Breast cancer risk associated with genotype polymorphism of the estrogenmetabolizing genes CYP17, CYP1A1, and COMT: A multigenic study on cancer susceptibility
76. Sex hormones in women in rural China and in Britain
77. Serum sex hormone levels after menopause and subsequent breast cancer
78. Endogenous estrogen and postmenopausal breast cancer: A quantitative review
79. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer
80. Breast patterns as an index of risk for developing breast cancer
81. Radiographic microcalcification and parenchymal pattern as indicators of histologic "high-risk" benign breast disease
82. Macronutrient intake and change in mammographic density at menopause: Results from a randomized trial
83. Effects of estrogen and estrogen-progestin on mammographic parenchymal density
84. Can mammographic densities predict effects of tamoxifen on the breast?
85. The detection of changes in mammographic densities
86. The relation of mammographic features of the breast to breast cancer risk factors
87. Mammographic densities and risk of breast cancer
88. Mammographic densities and risk of breast cancer among subjects with a family history of this disease
89. Mammographic parenchymal patterns as indicators of breast cancer risk
90. Genetic analysis of mammographic breast density in adult women: Evidence of a gene effect
91. The mammographic parenchymal patterns of nulliparous women and women with a family history of breast cancer
92. Mammographic patterns as a predictive biomarker of breast cancer risk: Effect of tamoxifen
93. The relationship of endogenous estrogen to bone density and bone area in normal postmenopausal women
94. Cytokines, estrogen, and postmenopausal osteoporosis - The second decade
95. Reduced risk of breast and endometrial cancer among women with hip fractures
96. Reduced cancer morbidity and mortality in a prospective cohort of women with distal forearm fractures
97. Bone mineral density and risk of breast cancer: Differences by family history of breast cancer
98. BRCA1 inhibition of estrogen receptor signaling in transfected cells
99. BRCA1 expression is not directly responsive to estrogen
100. Determinants of peak trabecular bone density in women: The role of androgens, estrogen, and exercise
101. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
102. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women: Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial